FDA Approves Lymphir Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Citius Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant Tcells and Tregs. This is the first indication for Lymphir and the first FDA-approved product for Citius Pharma.
- Lymphir provides another viable option in the treatment landscape with unique benefits to patients. It offers a novel mechanism of action designed to target and eradicate malignant T-cells while preserving healthy tissue. It is the only treatment option that targets the IL-2 receptors found in T-cell lymphomas and Tregs.
Source: Citius Pharmaceuticals, Inc
